CurveBeam AI (ASX:CVB) signed a commercial agreement with medical device manufacturer Stryker Australia for the Australia and New Zealand markets, according to a Tuesday filing with the Australian bourse.
Stryker will educate surgeons and promote the company's weight-bearing computed tomography imaging device HiRise for use in lower extremity orthopedic applications under the deal, the filing said.
The agreement, with an initial term of three years and a further term of two years, requires minimum referral volumes for sales and commissions to continue, per the filing.
CurveBeam AI shares were down 4% in afternoon trade Friday.
Price (AUD): $0.11, Change: $-0.0050, Percent Change: -4.35%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.